Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NSHO-101 in Healthy Participants
NCT07403552Phase 1Recruiting
- Sponsor
- Ensho Therapeutics
- Start
- Jan 2026
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of EA1080 in inflammatory bowel disease (IBD) (2 arms), sponsored by Ensho Therapeutics. Primary endpoints: Maximum Concentration, Area Under the Concentration Curve and 3 more. Started Jan 2026; status: recruiting.
02
Drugs
EA1080
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07403552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07403552.